Benlysta Autoinject is a prescription medication used to treat lupus, a chronic autoimmune disease that can cause inflammation and damage to various organs and tissues in the body. Benlysta works by blocking a specific protein in the body that contributes to the immune system attacking healthy tissues.
Benlysta Autoinject is available in a pre-filled autoinjector that is injected subcutaneously (under the skin) every 4 weeks. The recommended dosage is based on the patient's weight and is administered by a healthcare professional.
Benlysta Autoinject is an effective treatment option for lupus patients who have not responded well to other treatments or have experienced adverse side effects from them. Studies have shown that Benlysta can reduce lupus disease activity, improve symptoms, and prevent flares.
Like all medications, Benlysta Autoinject can cause side effects. Some common side effects include nausea, diarrhea, fever, headache, and fatigue. Patients may also experience injection site reactions, such as redness, swelling, and pain. It is important to inform your healthcare provider if you experience any side effects, as they can help manage them and adjust your dosage if necessary.
Benlysta Autoinject should not be used in patients who have had a severe allergic reaction to belimumab (the active ingredient in Benlysta) or any of its components. It is also important to inform your healthcare provider if you have a history of depression or other mental health conditions, as Benlysta can exacerbate these conditions. Patients should also inform their healthcare provider of all other medications they are taking, as Benlysta may interact with certain drugs.
Pregnancy and Breastfeeding:
It is not known whether Benlysta Autoinject can harm an unborn baby. Pregnant women should only use Benlysta if it is clearly needed and the benefits outweigh the risks. It is also not known whether Benlysta is excreted in human milk. Breastfeeding women should consult with their healthcare provider before using Benlysta.
Benlysta Autoinject is an effective and well-tolerated treatment option for lupus patients. It is administered subcutaneously every 4 weeks and can reduce lupus disease activity, improve symptoms, and prevent flares. As with all medications, it is important to inform your healthcare provider of any side effects and to follow their instructions regarding dosage and administration. Pregnant and breastfeeding women should consult with their healthcare provider before using Benlysta.